ElifOralMD

Endocrinology • Ann Arbor, MI

Diabetes, Lipid Metabolism

Endocrinologist, Metabolism Endocrinology Diabetes & Podiatry Clinic

Join to view full profile

Dr. Oral is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Oral's full profile

Already have an account?

Office
24 Frank Lloyd Wright Dr
Lobby C Suite 1300
Ann Arbor, MI 48105
Phone+1 734-998-2450

Education & Training

National Institutes of Health Clinical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1996 - 1999
Detroit Medical Center/Wayne State UniversityResidency, Internal Medicine, 1993 - 1996
Istanbul University FomClass of 1992

Certifications & Licensure

MI State Medical License 1993 - 2027
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Fellow (FACE) American Association of Clinical Endocrinology

Clinical Trials

Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2006 Feb 01
Completed
Phase 2
Effect of Macrocomposition on Nonalcoholic Fatty Liver Disease (NAFLD) in Bariatric Surgery Candidates Start of enrollment: 2009 Apr 01
Completed
Not Applicable
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus Start of enrollment: 2010 Jun 18
Completed
Phase 3
Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy Start of enrollment: 2012 Oct 08
Completed
Phase 2
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese Start of enrollment: 2012 Dec 01
Terminated
Not Applicable
Amlexanox for Type 2 Diabetes and Obesity Start of enrollment: 2013 Jul 19
Terminated
Phase 2
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients Start of enrollment: 2014 Jan 01
Completed
Phase 2
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia Start of enrollment: 2016 Dec 01
Completed
Phase 2
Study of Gemcabene in Adults With FPLD Start of enrollment: 2018 Mar 13
Completed
Phase 1, Phase 2
Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy Start of enrollment: 2018 Nov 14
Active, not recruiting
Phase 4
Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL) Start of enrollment: 2023 Aug 01
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

97 citations
Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy.
Elif A. Oral, Elaine Ruiz, Alexa Andewelt, Nancy G. Sebring, Anthony J. Wagner
The Journal of Clinical Endocrinology and Metabolism. 2002-07-01
841 citations
Leptin-replacement therapy for lipodystrophy.
Elif A. Oral, Vinaya Simha, Elaine Ruiz, Alexa Andewelt, Ahalya Premkumar
The New England Journal of Medicine. 2002-02-21
567 citations
Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy
Kitt Falk Petersen, Elif A. Oral, Sylvie Dufour, Douglas E. Befroy, Charlotte E. Ariyan
The Journal of Clinical Investigation. 2002-05-15

Journal Articles

Metabolic Parameters, Weight Loss, and Comorbidities 4 Years After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy
Elif A Oral, Nazanene H Esfandiari, Colleen M Buda, Corey J Lager, Oliver A Varban, Andrew T Kraftson, Obesity Surgery

Press Mentions

New Potential Therapy for Fatty Liver DiseaseJune 7th, 2021
Gemphire Announces Termination of Phase 2a Clinical Trial of Gemcabene in Pediatric NAFLDAugust 10th, 2018
Michigan Medicine's Division of Metabolism, Endocrinology and Diabetes Showcases New Research at Endocrine Society's ENDO 2018March 17th, 2018
Join now to see all